Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03184558
Title BGB324 in Combination With Pembrolizumab in Patients With TNBC
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors BerGenBio ASA

triple-receptor negative breast cancer


Bemcentinib + Pembrolizumab

Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.